Literature DB >> 29312521

Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast.

Sung-Im Do1, Hyun-Soo Kim2, Kyungeun Kim1, Hyunjoo Lee1, In-Gu Do1, Dong-Hoon Kim1, Seoung Wan Chae1, Jin Hee Sohn1.   

Abstract

Sphingosine kinase 1 (SPHK1) has been found to be upregulated in many different types of human malignancy and plays a crucial role in cancer development and progression. However, the potential of SPHK1 to act as a predictive and prognostic biomarker in breast cancer remains to be clarified. In the present study, SPHK1 expression was evaluated in breast cancer cell lines and 224 breast cancer tissue samples using immunohistochemical staining. Compared to the normal mammary epithelial cell line MCF-10A, SPHK1 mRNA and protein expression levels increased in the breast cancer cell lines SK-BR-3, MDA-MB-231, MDA-MB-436, and MCF-7. Immunohistochemical staining revealed SPHK1 expression to be significantly increased in breast cancer tissue compared to normal breast tissue, with 85 (37.9%) of the 224 invasive ductal carcinomas (IDC) exhibiting high SPHK1 expression. High SPHK1 expression in IDC showed a significant association with higher histological grade, distant metastasis, and triple negativity, and was shown to be an independent predictor for distant metastasis development. In addition, patients with high SPHK1 expression had significantly lower progression-free survival and overall survival rates compared to those with low SPHK1 expression. Our data suggest that SPHK1 is involved in the development and progression of breast cancer and can serve as a potential predictive biomarker of distant metastasis and patient outcome.

Entities:  

Keywords:  Breast; immunohistochemistry; invasive ductal carcinoma; metastasis; sphingosine kinase 1; survival

Year:  2017        PMID: 29312521      PMCID: PMC5752919     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens.

Authors:  Bernard Malavaud; Dimitri Pchejetski; Catherine Mazerolles; Geisilène Russano de Paiva; Cyril Calvet; Nicolas Doumerc; Stuart Pitson; Pascal Rischmann; Olivier Cuvillier
Journal:  Eur J Cancer       Date:  2010-10-20       Impact factor: 9.162

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.

Authors:  James R Van Brocklyn; Catherine A Jackson; Dennis K Pearl; Mark S Kotur; Pamela J Snyder; Thomas W Prior
Journal:  J Neuropathol Exp Neurol       Date:  2005-08       Impact factor: 3.685

5.  Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions.

Authors:  Michael G Bayerl; Richard D Bruggeman; Elizabeth J Conroy; Jeremy A Hengst; Tonya S King; Marcela Jimenez; David F Claxton; Jong K Yun
Journal:  Leuk Lymphoma       Date:  2008-05

6.  Role for sphingosine kinase 1 in colon carcinogenesis.

Authors:  Toshihiko Kawamori; Tatsuya Kaneshiro; Masae Okumura; Samer Maalouf; Andre Uflacker; Jacek Bielawski; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2008-09-29       Impact factor: 5.191

7.  High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.

Authors:  Yukihiro Akao; Yoshiko Banno; Yoshihito Nakagawa; Nobuko Hasegawa; Tack-Joong Kim; Takashi Murate; Yasuyuki Igarashi; Yoshinori Nozawa
Journal:  Biochem Biophys Res Commun       Date:  2006-02-21       Impact factor: 3.575

8.  Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: a need for reappraisal.

Authors:  Nara Yoon; Ji-Ye Kim; Hyun-Soo Kim
Journal:  Oncotarget       Date:  2016-11-29

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

10.  The impact of sphingosine kinase-1 in head and neck cancer.

Authors:  Paulette M Tamashiro; Hideki Furuya; Yoshiko Shimizu; Kayoko Iino; Toshihiko Kawamori
Journal:  Biomolecules       Date:  2013-08-12
View more
  2 in total

1.  Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Authors:  Mei Wu; Qi Sun; Chao-Hua Mo; Jin-Shu Pang; Jia-Yin Hou; Ling-Ling Pang; Hui-Ping Lu; Yi-Wu Dang; Su-Jie Fang; Deng Tang; Gang Chen; Zhen-Bo Feng
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

Review 2.  Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.

Authors:  Heba Alshaker; Hannah Thrower; Dmitri Pchejetski
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.